|
1
|
Geisler F and Strazzabosco M: Emerging
roles of Notch signaling in liver disease. Hepatology. 61:382–392.
2015. View Article : Google Scholar
|
|
2
|
Ding J and Wang H: Multiple interactive
factors in hepatocarcinogenesis. Cancer Lett. 346:17–23. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huang J, Xu L, Luo Y, He F, Zhang Y and
Chen M: The inflammation-based scores to predict prognosis of
patients with HCC after hepatectomy. Med Oncol. 31:8832014.
View Article : Google Scholar
|
|
4
|
Coulouarn C and Clément B: Stellate cells
and the development of liver cancer: Therapeutic potential of
targeting the stroma. J Hepatol. 60:1306–1309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cervello M, McCubrey JA, Cusimano A,
Lampiasi N, Azzolina A and Montalto G: Targeted therapy for HCC:
Novel agents on the horizon. Oncotarget. 3:236–260. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stauffer JK, Scarzello AJ, Jiang Q and
Wiltrout RH: Chronic inflammation, immune escape, and oncogenesis
in the liver: A unique neighborhood for novel intersections.
Hepatology. 56:1567–1574. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bruix J and Sherman M; Practice Guidelines
Committee, American Association for the Study of Liver Diseases:
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng AL, Kang YK, He AR, Lim HY, Ryoo BY,
Hung CH, Sheen IS, Izumi N, Austin T, Wang Q, et al: Safety and
efficacy of tigatuzumab plus sorafenib as first-line therapy in
subjects with advanced hepatocellular carcinoma: a phase 2
randomized study. J Hepatol. 63:896–904. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tutunea-Fatan E, Caetano FA, Gros R and
Ferguson SS: GRK2 targeted knock-down results in spontaneous
hypertension, and altered vascular GPCR signaling. J Biol Chem.
290:5141–5155. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Penela P, Ribas C, Aymerich I, Eijkelkamp
N, Barreiro O, Heijnen CJ, Kavelaars A, Sánchez-Madrid F and Mayor
F Jr: G protein-coupled receptor kinase 2 positively regulates
epithelial cell migration. EMBO J. 27:1206–1218. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma L and Pei G: β-arrestin signaling and
regulation of transcription. J Cell Sci. 120:213–218. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo J, Chen H, Ho J, Mancini J, Sontag T,
Laporte SA, Richard DE and Lebrun JJ: TGFbeta-induced GRK2
expression attenuates AngII-regulated vascular smooth muscle cell
proliferation and migration. Cell Signal. 21:899–905. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang X, Yang P and Ma L: Kinase
activity-independent regulation of cyclin pathway by GRK2 is
essential for zebrafish early development. Proc Natl Acad Sci USA.
106:10183–10188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Avendaño MS, Lucas E, Jurado-Pueyo M,
Martínez-Revelles S, Vila-Bedmar R, Mayor F Jr, Salaices M, Briones
AM and Murga C: Increased nitric oxide bioavailability in adult
GRK2 hemizygous mice protects against angiotensin II-induced
hypertension. Hypertension. 63:369–375. 2014. View Article : Google Scholar
|
|
15
|
Lymperopoulos A, Rengo G, Funakoshi H,
Eckhart AD and Koch WJ: Adrenal GRK2 upregulation mediates
sympathetic overdrive in heart failure. Nat Med. 13:315–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liang XH, Deng WB, Li M, Zhao ZA, Wang TS,
Feng XH, Cao YJ, Duan EK and Yang ZM: Egr1 protein acts downstream
of estrogen-leukemia inhibitory factor (LIF)-STAT3 pathway and
plays a role during implantation through targeting Wnt4. J Biol
Chem. 289:23534–23545. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chu L, Wang T, Hu Y, Gu Y, Su Z and Jiang
H: Activation of Egr-1 in human lung epithelial cells exposed to
silica through MAPKs signaling pathways. PLoS One. 8:e689432013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grotegut S, von Schweinitz D, Christofori
G and Lehembre F: Hepatocyte growth factor induces cell scattering
through MAPK/Egr-1-mediated upregulation of Snail. EMBO J.
25:3534–3545. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma Y, Cheng Q, Ren Z, Xu L, Zhao Y, Sun J,
Hu S and Xiao W: Induction of IGF-1R expression by EGR-1
facilitates the growth of prostate cancer cells. Cancer Lett.
317:150–156. 2012. View Article : Google Scholar
|
|
20
|
Ma J, Ren Z, Ma Y, Xu L, Zhao Y, Zheng C,
Fang Y, Xue T, Sun B and Xiao W: Targeted knockdown of EGR-1
inhibits IL-8 production and IL-8-mediated invasion of prostate
cancer cells through suppressing EGR-1/NF-kappaB synergy. J Biol
Chem. 284:34600–34606. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng H, Worrall C, Shen H, Issad T,
Seregard S, Girnita A and Girnita L: Selective recruitment of G
protein-coupled receptor kinases (GRKs) controls signaling of the
insulin-like growth factor 1 receptor. Proc Natl Acad Sci USA.
109:7055–7060. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peppel K, Jacobson A, Huang X, Murray JP,
Oppermann M and Freedman NJ: Overexpression of G protein-coupled
receptor kinase-2 in smooth muscle cells attenuates mitogenic
signaling via G protein-coupled and platelet-derived growth factor
receptors. Circulation. 102:793–799. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Métayé T, Levillain P, Kraimps JL and
Perdrisot R: Immunohistochemical detection, regulation and
antiproliferative function of G-protein-coupled receptor kinase 2
in thyroid carcinomas. J Endocrinol. 198:101–110. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wei Z, Hurtt R, Gu T, Bodzin AS, Koch WJ
and Doria C: GRK2 negatively regulates IGF-1R signaling pathway and
cyclins' expression in HepG2 cells. J Cell Physiol. 228:1897–1901.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Criswell T, Beman M, Araki S, Leskov K,
Cataldo E, Mayo LD and Boothman DA: Delayed activation of
insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling
regulates clusterin expression, a pro-survival factor. J Biol Chem.
280:14212–14221. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mueller L, Broering DC, Meyer J, Vashist
Y, Goettsche J, Wilms C and Rogiers X: The induction of the
immediate-early-genes Egr-1, PAI-1 and PRL-1 during liver
regeneration in surgical models is related to increased portal
flow. J Hepatol. 37:606–612. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kawashıta Y, Ohtsuru A, Kaneda Y, Nagayama
Y, Kawazoe Y, Eguchi S, Kuroda H, Fujioka H, Ito M, Kanematsu T, et
al: Regression of HCC in vitro and in vivo by radiosensitizing
suicide gene therapy under the inducible and spatial control of
radiation. Hum Gene Ther. 10:1509–1519. 1999. View Article : Google Scholar
|
|
28
|
Hao MW, Liang YR, Liu YF, Liu L, Wu MY and
Yang HX: Transcription factor EGR1 inhibits growth of HCC and
esophageal carcinoma cell lines. World J Gastroenterol. 2:203–207.
2002.
|
|
29
|
Lee KH and Kim JR: Hepatocyte growth
factor induced up-regulations of VEGF through Egr-1 in
hepatocellular carcinoma cells. Clin Exp Metastasis. 26:685–692.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ozen E, Gozukizil A, Erdal E, Uren A,
Bottaro DP and Atabey N: Heparin inhibits Hepatocyte Growth Factor
induced motility and invasion of hepatocellular carcinoma cells
through early growth response protein 1. PLoS One. 7:e427172012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shin SY, Kim JH, Baker A, Lim Y and Lee
YH: Transcription factor Egr-1 is essential for maximal matrix
metalloproteinase-9 transcription by tumor necrosis factor alpha.
Mol Cancer Res. 8:507–519. 2010. View Article : Google Scholar : PubMed/NCBI
|
